23andMe has raised $250 million in funding, the consumer genomics firm announced today.

23andMe said it plans to use the money to grow its customer base, expand its therapeutics group, and invest in its genetic research platform. With this latest funding, 23andMe has raised $491 million from a range of investors, including technology and health science companies, angel investors, and venture capital firms.

This funding round was led by Sequoia Capital and included Euclidean Capital, Altimeter Capital, and the Wallenberg Foundation, all new investors in 23andMe. Current investors Fidelity Management & Research Company and Casdin Capital also contributed funding.

Roelof Botha, partner at Sequoia Capital, will join 23andMe's board of directors. The firm also noted that Neal Mohan, chief product officer at YouTube and a senior VP at Google, joined the board in July.